Literature DB >> 22427632

Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.

Takemasa Tsuji1, Junko Matsuzaki, Otavia L Caballero, Achim A Jungbluth, Gerd Ritter, Kunle Odunsi, Lloyd J Old, Sacha Gnjatic.   

Abstract

Tumor Ag-specific CD4(+) T cells play important functions in tumor immunosurveillance, and in certain cases they can directly recognize HLA class II-expressing tumor cells. However, the underlying mechanism of intracellular Ag presentation to CD4(+) T cells by tumor cells has not yet been well characterized. We analyzed two naturally occurring human CD4(+) T cell lines specific for different peptides from cytosolic tumor Ag NY-ESO-1. Whereas both lines had the same HLA restriction and a similar ability to recognize exogenous NY-ESO-1 protein, only one CD4(+) T cell line recognized NY-ESO-1(+) HLA class II-expressing melanoma cells. Modulation of Ag processing in melanoma cells using specific molecular inhibitors and small interfering RNA revealed a previously undescribed peptide-selective Ag-presentation pathway by HLA class II(+) melanoma cells. The presentation required both proteasome and endosomal protease-dependent processing mechanisms, as well as cytosolic heat shock protein 90-mediated chaperoning. Such tumor-specific pathway of endogenous HLA class II Ag presentation is expected to play an important role in immunosurveillance or immunosuppression mediated by various subsets of CD4(+) T cells at the tumor local site. Furthermore, targeted activation of tumor-recognizing CD4(+) T cells by vaccination or adoptive transfer could be a suitable strategy for enhancing the efficacy of tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427632     DOI: 10.4049/jimmunol.1103269

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  The elucidation of non-classical MHC class II antigen processing through the study of viral antigens.

Authors:  Asha Purnima Veerappan Ganesan; Laurence C Eisenlohr
Journal:  Curr Opin Virol       Date:  2017-01-12       Impact factor: 7.090

2.  Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Authors:  Junko Matsuzaki; Takemasa Tsuji; Immanuel Luescher; Lloyd J Old; Protul Shrikant; Sacha Gnjatic; Kunle Odunsi
Journal:  Cancer Immunol Res       Date:  2013-12-17       Impact factor: 11.151

Review 3.  Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.

Authors:  Thinle Chodon; Amit A Lugade; Sebastiano Battaglia; Kunle Odunsi
Journal:  Hematol Oncol Clin North Am       Date:  2018-10-01       Impact factor: 3.722

4.  Chaperones: needed for both the good times and the bad times.

Authors:  Roy A Quinlan; R John Ellis
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-03-25       Impact factor: 6.237

5.  Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.

Authors:  Kenji Sugata; Yukiko Matsunaga; Yuki Yamashita; Munehide Nakatsugawa; Tingxi Guo; Levon Halabelian; Yota Ohashi; Kayoko Saso; Muhammed A Rahman; Mark Anczurowski; Chung-Hsi Wang; Kenji Murata; Hiroshi Saijo; Yuki Kagoya; Dalam Ly; Brian D Burt; Marcus O Butler; Tak W Mak; Naoto Hirano
Journal:  Nat Biotechnol       Date:  2021-03-01       Impact factor: 54.908

6.  Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Authors:  P Baumgaertner; C Costa Nunes; A Cachot; H Maby-El Hajjami; L Cagnon; M Braun; L Derré; J-P Rivals; D Rimoldi; S Gnjatic; S Abed Maillard; P Marcos Mondéjar; M P Protti; E Romano; O Michielin; P Romero; D E Speiser; C Jandus
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

Review 7.  Diverse cellular and organismal functions of the lysosomal thiol reductase GILT.

Authors:  Matthew P Rausch; Karen Taraszka Hastings
Journal:  Mol Immunol       Date:  2015-06-23       Impact factor: 4.407

8.  High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.

Authors:  Kenneth H Buetow; Lydia R Meador; Hari Menon; Yih-Kuang Lu; Jacob Brill; Haiyan Cui; Denise J Roe; David J DiCaudo; K Taraszka Hastings
Journal:  J Immunol       Date:  2019-10-07       Impact factor: 5.422

9.  Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.

Authors:  Jennifer Nguyen; Richard Bernert; Kevin In; Paul Kang; Noemi Sebastiao; Chengcheng Hu; K Taraszka Hastings
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

10.  Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.

Authors:  Takemasa Tsuji; Akira Yoneda; Junko Matsuzaki; Anthony Miliotto; Courtney Ryan; Richard C Koya; Kunle Odunsi
Journal:  Cancer Immunol Res       Date:  2018-03-27       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.